Skip to main content

Table 5 Clinical and socio-demographic factors associated with not getting DST among patients with presumptive MDR-TB, District Bhopal, India (2014)

From: High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India

Variable

Total

Not tested for

RR (0.95 CI)

aRR (0.95 CI)a

[n]

DST [n (%)]

  

Total

770

459 (60)

  

Age (years)

 • <14

7

4 (57)

0.9 (0.5, 1.9)

1.0 (0.6, 1.9)

 • 14-44

513

301 (59)

1.0 (0.9, 1.2)

1.0 (0.9, 1.2)

 • 45-64

203

118 (58)

Ref

Ref

 • >/= 65

47

36 (77)

1.3 (1.1, 1.6)*

1.3 (1.1, 1.7)*

Gender

 • Male

520

314 (60)

1.0 (0.9, 1.2)

1.1 (1.0, 1.2)

 • Female

250

145 (58)

Ref

Ref

Health facility

    

 • Primary/Secondary level

362

208 (58)

1.0 (0.9, 1.1)

1.0 (0.9, 1.1)

 • District level

273

159 (58)

Ref

Ref

 • Medical college

135

92 (68)

1.2 (1.00, 1.4)

1.2 (1.02, 1.4)*

Presumptive MDR-TB criteria

 • Previously treated – recurrent

251

128 (51)

1.2 (0.9,1.5)

1.3 (1.0, 1.6)*

 • Treatment after failure

22

11 (50)

1.2 (0.7, 1.9)

1.3 (0.8, 2.0)

 • Treatment after loss to follow up

51

33 (65)

1.5 (1.2, 2.0)*

1.5 (1.1, 2.1)*

 • Previously treated – others

311

229 (74)

1.7 (1.4, 2.1)*

1.6 (1.1, 2.3)*

 • Follow up smear +

132

56 (42)

Ref

Ref

 • New patient with TB-HIV

3

2 (67)

1.6 (0.7,3.6)

1.8 (0.8, 4.2)

Site of Tuberculosis

 • Extra pulmonary

89

72 (81)

1.6 (1.4, 1.9)*

1.5 (1.0, 2.2)*

 • Pulmonary – smear negative

248

172 (69)

1.4 (1.2, 1.6)*

1.2 (0.8, 1.7)

 • Pulmonary – smear positive

433

215 (50)

Ref

Ref

Quarter

 • January – March 2014

101

63 (62)

Ref

Ref

 • April – June 2014b

238

144 (61)

0.97 (0.8, 1.2)

0.8 (0.7, 0.98)*

 • July – September 2014

223

132 (59)

0.95 (0.8, 1.1)

0.8 (0.7, 0.99)*

 • October – December 2014

208

120 (58)

0.9 (0.8, 1.1)

0.8 (0.6, 0.95)*

  1. MDR-TB Multi drug-resistant tuberculosis, DST Drug susceptibility testing
  2. aadjusted relative risk calculated using poisson regression with robust variance estimates (enter method)
  3. *p < 0.05
  4. bLPA was used as DST for smear positive patient; Cb-NAAT was introduced as DST for smear negative patient in quarter 2